NEW YORK (360Dx) – Qiagen said today that it has submitted its QuantiFeron-TB Gold Plus assay for latent tuberculosis detection to the US Food and Drug Administration for pre-market approval.

The US submission follows on the company's 2016 launch of the CE marked assay in more than 60 countries in Europe, the Middle East, Africa, Asia, and Latin America. More than 600,000 of the tests have been used thus far in those countries, Qiagen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.